Does Iris Color Affect Atropine?

Overview

A post-hoc meta-analysis suggests that while safety-related ocular effects of low-dose atropine are consistent across different iris colors, treatment efficacy may vary. Children with non-brown irides showed significant myopia progression reduction with atropine 0.01%, while those with brown irides did not.

Background

Low-dose atropine is increasingly used in myopia management among children. Understanding factors that influence its efficacy, such as iris color, is crucial. This analysis provides insights into potential differences in treatment response based on iris pigmentation.

Data Highlights

Key Findings

• Atropine 0.01% reduced myopia progression in children with non-brown irides.
• No significant treatment effect was observed in children with brown irides at the same concentration.
• Atropine's safety profile was consistent across different iris colors.
• Higher concentrations of atropine (0.05%) did not show iris color-related differences in efficacy.
• Pharmacokinetics may explain the differential efficacy based on iris color.

Clinical Implications

Clinicians should consider the findings regarding iris color and treatment response.

Conclusion

The findings highlight the need for further exploration of individualized atropine dosing based on iris color, although current evidence is exploratory and not yet definitive.

Related Resources & Content

1. Low-concentration atropine for management of myopia progression: does iris colour matter? Eye, 2026 -- Eye
2. Ophthalmology Management — Short Term Effects of Low Concentration Atropine on Ocular Structure
3. Optometric Management — ShortTerm Effects of LowConcentration Atropine on Ocular Structure
4. Optometric Management — LEADING OFF: O.D.s Discuss Where They Acquire Atropine
5. Contact Lens Spectrum — ATROPINE—WHAT’S IN THE BOTTLE?
6. Short Term Effects of Low Concentration Atropine on Ocular Structure
7. LEADING OFF: O.D.s Discuss Where They Acquire Atropine
8. IMI Interventions for Controlling Myopia Onset and Progression 2025 - Myopia Institute
9. https://wspos.org/wp-content/uploads/2025/04/Draft-Myopia-Consensus-Statement-28th-April-2025.pdf
10. Ryjunea | European Medicines Agency (EMA)
11. European Commission Approves Santen’s Ryjunea® to Slow Progression of Paediatric Myopia
12. Sydnexis Receives Complete Response Letter from FDA for SYD-101 to Slow Pediatric Myopia Progression
13. AOA Statement to FDA on Low-Dose Atropine | AOA
14. Five-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study: Phase 4 Report - PubMed
15. Five-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study: Phase 4 Report - ScienceDirect
16. Efficacy and Safety of Different Atropine Regimens for the Treatment of Myopia in Children: Three-Year Results of the MOSAIC Randomized Clinical Trial - PMC
17. Dublin-based atropine trial reports three-year results
18. Low-Dose 0.01% Atropine Eye Drops vs Placebo for Myopia Control: A Randomized Clinical Trial - PMC
19. Efficacy and Safety of 0.01% and 0.02% Atropine for the Treatment of Pediatric Myopia Progression Over 3 Years: A Randomized Clinical Trial - PMC
20. Efficacy and Safety of 0.01% and 0.02% Atropine for the Treatment of Pediatric Myopia Progression Over 3 Years
21. Is Recommending 0.01% Atropine for Myopia Control Clinically Meaningful? | JAMA Ophthalmology | JAMA Network
22. Efficacy, tolerability, and threshold effect of atropine eye drops for myopia control: A systematic review and dose-response meta-analysis - ScienceDirect
23. Dose-Dependent Effects of Atropine on Accommodative and Binocular Visual Function for Myopia Control in Children: A Systematic Review and Meta-Analysis | Ophthalmic and Physiological Optics | Springer Nature Link
24. Low-concentration atropine for management of myopia progression: does iris colour matter? | Eye